Janus Henderson Group PLC increased its position in Bristol-Myers Squibb Co (NYSE:BMY) by 75.7% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 16,156,559 shares of the biopharmaceutical company’s stock after purchasing an additional 6,960,047 shares during the period. Janus Henderson Group PLC owned about 0.99% of Bristol-Myers Squibb worth $732,691,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of the stock. Cutter & CO Brokerage Inc. purchased a new stake in Bristol-Myers Squibb in the 2nd quarter worth approximately $1,613,000. Canal Capital Management LLC purchased a new stake in Bristol-Myers Squibb in the 2nd quarter worth approximately $1,943,000. Gould Asset Management LLC CA lifted its position in Bristol-Myers Squibb by 8.9% in the 2nd quarter. Gould Asset Management LLC CA now owns 11,779 shares of the biopharmaceutical company’s stock worth $534,000 after buying an additional 965 shares in the last quarter. Municipal Employees Retirement System of Michigan lifted its position in Bristol-Myers Squibb by 92.6% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 42,560 shares of the biopharmaceutical company’s stock worth $1,930,000 after buying an additional 20,460 shares in the last quarter. Finally, Coastal Capital Group Inc. purchased a new stake in Bristol-Myers Squibb in the 2nd quarter worth approximately $89,000. 80.11% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts have issued reports on BMY shares. Barclays upgraded shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $53.00 to $55.00 in a research report on Friday, May 3rd. JPMorgan Chase & Co. started coverage on shares of Bristol-Myers Squibb in a research report on Friday, May 3rd. They issued an “overweight” rating and a $62.00 target price for the company. UBS Group cut their target price on shares of Bristol-Myers Squibb from $55.00 to $51.00 and set a “neutral” rating for the company in a research report on Thursday, June 13th. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $54.00 target price for the company in a research report on Tuesday, May 7th. Finally, ValuEngine upgraded shares of Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a research report on Monday. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company’s stock. Bristol-Myers Squibb has an average rating of “Hold” and an average target price of $55.88.
Bristol-Myers Squibb stock opened at $48.66 on Thursday. The company has a market capitalization of $78.70 billion, a P/E ratio of 12.23, a P/E/G ratio of 2.37 and a beta of 0.73. The firm’s fifty day simple moving average is $45.69 and its 200-day simple moving average is $47.33. The company has a current ratio of 3.88, a quick ratio of 3.75 and a debt-to-equity ratio of 1.51. Bristol-Myers Squibb Co has a 1-year low of $42.48 and a 1-year high of $63.69.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share for the quarter, beating analysts’ consensus estimates of $1.06 by $0.12. The business had revenue of $6.27 billion for the quarter, compared to the consensus estimate of $6.10 billion. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. Bristol-Myers Squibb’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.01 EPS. On average, equities research analysts predict that Bristol-Myers Squibb Co will post 4.28 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Thursday, August 1st. Investors of record on Friday, July 5th were issued a $0.41 dividend. The ex-dividend date of this dividend was Wednesday, July 3rd. This represents a $1.64 annualized dividend and a yield of 3.37%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 41.21%.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
See Also: How to Invest in a Bull Market
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.